ArticleInternational journal of clinical and experimental pathology2017
Cardioprotective effect of indirubin in experimentally induced myocardial infarction in wistar rats.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, there has been as enhanced interest on global level to recognize the potent antioxidant compounds which are pharmacologically active with less or no side effects. Thus, the current investigation was intended to scrutinize the protective effect of indirubin on the cardiac marker, such as, enzymes, LDH isoenzyme, cardiac troponin-T (cTnT), antioxidant enzymes marker and lipid peroxidation (LPO) in response of isoproterenol (ISO)-induced myocardial infarction (MI) in Wistar rats. The experimental animals were categorized into following groups: Group I received saline; Group II received Indirubin (10 mg/kg); Group III received ISO (100 mg/kg) and Group IV received ISO + indirubin (10 mg/kg) for continuous 10 days. The ISO induced MI injury was confirmed via enhanced level of enzymes markers viz., creatine kinase-MB, creatine kinase, lactate dehydrogensae, troponin-T, alanine transaminase (ALT) and aspartate transaminase (AST) in the rats serum. The enhanced expression of LDH (1 and 2) isoenzyme bands were also observed in the ISO induced MI rats. We have also estimated the level of LPO in the heart and plasma, which was found to be significantly (P<0.05) improved. Moreover, the marker of enzymatic antioxidant enzymes viz., glutathione reductase (GRx), catalase (CAT), glutathione-S-transferase (GST), glutathione peroxidase (GPx) and superoxide dismutase (SOD) in the heart, and the level of non-enzymatic antioxidant marker viz., vitamin (C, E) in heart and serum were found to be considerably (P<0.05) reduced in the ISO induced MI in Wistar rats. Whereas, the ISO control Wistar rats showed significant (P<0.05) increase in the uric acid level in the plasma. The Indirubin treated rats confirmed the significant protective effect via modulation of all biological and antioxidant parameters tested. The result of the investigation was further found in agreement of the histopathological studies of the indirubin treated rats which clearly showed recovery from the myocardial infarction. Thus, on the basis of that, it has been suggested that indirubin showed protection of myocardial tissues against the ISO persuaded oxidative stress.
Indexed as
Identifiers
31966661PMC6965302W3026238186What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.